Literature DB >> 15813837

Is the management of hepatitis C patients appropriate? A population-based study.

C Hatem1, A Minello, S Bresson-Hadni, V Jooste, P Evrard, B Obert, C Lepage, C Bonithon-Kopp, J Faivre, E Monnet, J-P Miguet, P Hillon.   

Abstract

BACKGROUND: In order for hepatitis C patients to receive antiviral treatment, they must reach medical care. AIM: To assess the proportion of patients reaching medical care after hepatitis C diagnosis in a general population (1 006 171 inhabitants) in France.
METHODS: Between 1994 and 1999, 1508 cases were diagnosed, of which 1251 were eligible for the study.
RESULTS: Two-hundred and two patients did not have any medical care; among them, 55.4% had normal alanine transferase, 58.4% had risk factors related to lifestyle and 22.8% were alcoholics. Amongst the 1049 other patients, 41.6% had a liver biopsy, 25.0% were treated. Treatment was more often carried out in males than in females (OR: 1.59; P = 0.001), and in patients under 65 than in older patients (OR: 2.22; P < 0.008). Among non-treatment reasons, alcoholism (P = 0.001), drug-addiction (P = 0.04) and escaping monitoring (P = 0.04) were more frequent in males than in females, whereas normal alanine transferase was more frequent in females than in males (P = 0.004). Amongst 278 patients with a Metavir score >A1F1, 71 (25.5%) did not undergo treatment.
CONCLUSION: In a general population, one patient in six did not receive on-going health care; a quarter of patients with a Metavir score >A1F1 did not receive any treatment. These results showed insufficient clinical management, which could compromise the effectiveness of treatment in general population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15813837     DOI: 10.1111/j.1365-2036.2005.02393.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Access to treatment of hepatitis C in prison inmates.

Authors:  Paul Strock; Joël Mossong; Karine Hawotte; Vic Arendt
Journal:  Dig Dis Sci       Date:  2008-08-29       Impact factor: 3.199

2.  Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence.

Authors:  Peter Higgs; Rachel Sacks-Davis; Judy Gold; Margaret Hellard
Journal:  Hepat Mon       Date:  2011-07       Impact factor: 0.660

Review 3.  Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Authors:  Jennifer M Loftis; Annette M Matthews; Peter Hauser
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.

Authors:  K Neukam; J A Mira; I Gilabert; E Claro; M J Vázquez; C Cifuentes; S García-Rey; N Merchante; C Almeida; J Macías; J A Pineda
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-06       Impact factor: 3.267

5.  Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.

Authors:  Marilyn S Huckans; Jennifer M Loftis; Aaron D Blackwell; Alex Linke; Peter Hauser
Journal:  Subst Abuse Treat Prev Policy       Date:  2007-01-12

6.  Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review.

Authors:  Amirhossein Modabbernia; Hossein Poustchi; Reza Malekzadeh
Journal:  Hepat Mon       Date:  2013-01-07       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.